MDM2 gene amplification and protein expressions in colon carcinoma: Is targeting MDM2 a new therapeutic option?

Virchows Archiv

Volumn 458, Issue 2, 2011, Pages 197-203

  Hav, Monirath ^a   Libbrecht, Louis ^a   Ferdinande, Liesbeth ^a   Pattyn, Piet ^a   Laurent, Stephanie ^a   Peeters, Marc ^a   Praet, Marleen ^a   Pauwels, Patrick ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Colon carcinoma; MDM2; MDM2 gene amplification; MDM2 in colon carcinoma; MDM2 protein expression; Targeted treatment in colon carcinoma

Indexed keywords

PROTEIN MDM2;

ADULT; AGED; ARTICLE; COLON CARCINOMA; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL;

EID: 79951726364     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-1012-7     Document Type: Article

References (33)

1. M Farnebo VJ Bykov KG Wiman 2010 The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer Biochem Biophys Res Commun 396 1 85 89 1:CAS:528:DC%2BC3cXmsVGlsb4%3D 10.1016/j.bbrc.2010.02.152 20494116
2. A Ventura DG Kirsch ME McLaughlin, et al. 2007 Restoration of p53 function leads to tumour regression in vivo Nature 445 661 665 1:CAS:528:DC%2BD2sXhtlOrtbg%3D 10.1038/nature05541 17251932 (Pubitemid 46232887)
3. Y Qian X Chen 2010 Tumor suppression by p53: making cells senescent Histol Histopathol 25 4 515 526 1:CAS:528:DC%2BC3cXms1Okurg%3D 20183804
4. V Zuckerman K Wolyniec RV Sionov S Haupt Y Haupt 2009 Tumour suppression by p53: the importance of apoptosis and cellular senescence J Pathol 219 1 3 15 1:CAS:528:DC%2BD1MXhtFGgs7%2FP 19562738
5. J Momand D Jung S Wilczynski J Niland 1998 The MDM2 gene amplification database Nucleic Acids Res 26 15 3453 3459 1:CAS:528:DyaK1cXltlKqsr4%3D 10.1093/nar/26.15.3453 9671804 (Pubitemid 28347214)
6. A Forslund Z Zeng Li-Xuan Qin, et al. 2008 MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers Mol Cancer Res 6 2 205 211 1:CAS:528:DC%2BD1cXisVWhsrc%3D 10.1158/1541-7786.MCR-07-0239 18314481 (Pubitemid 351342408)
7. Spiessl B, Beahrs OH, Hermanek P et al (1992) UICC-TNM atlas. 3rd ed. 2nd Rev. Springer-Verlag, Berlin
8. Y Haupt R Maya A Kazaz M Aron 1997 MDM2 promotes the rapid degradation of p53 Nature 387 296 299 1:CAS:528:DyaK2sXjtlSgtL8%3D 10.1038/387296a0 9153395 (Pubitemid 27220766)
9. R Honda H Tanaka H Yasuda 1997 Oncoprotein MDM2 is a ubiquitin ligase E3 for tumour suppressor p53 FEBS Lett 420 25 27 1:CAS:528:DyaK2sXotVyjtrg%3D 10.1016/S0014-5793(97)01480-4 9450543 (Pubitemid 28037193)
10. JD Oliner JA Pictonpol S Thiagalingam J Gyeris KW Kinzler B Vogelstein 1993 Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature 362 6423 857 860 1:CAS:528:DyaK3sXkt1ait7g%3D 10.1038/362857a0 8479525 (Pubitemid 23132165)
11. SN Jones AE Roe LA Donehower A Bradley 1995 Rescue of embryonic lethality in MDM2-deficient mice by absence of p53 Nature 378 206 208 1:CAS:528:DyaK2MXptlSmtb0%3D 10.1038/378206a0 7477327
12. M de Oca R Luna DS Wagner G Lozano 1995 Rescue of early embryonic lethality in MDM2-deficient mice by deletion of p53 Nature 378 203 206 10.1038/378203a0
13. GL Bond W Hu EE Bond, et al. 2004 A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 5 591 602 1:CAS:528:DC%2BD2cXhtVGls7bF 10.1016/j.cell.2004.11.022 15550242 (Pubitemid 39535748)
14. LF Grochola TH Müller GL Bond, et al. 2010 MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation Pancreas 39 1 76 80 1:CAS:528:DC%2BD1MXhsFyhs7fI 10.1097/MPA.0b013e3181b9f105 19752772
15. K Onel C Cordon-Cardo 2004 MDM2 and prognosis Mol Cancer Res 2 1 1 8 1:CAS:528:DC%2BD2cXovVensw%3D%3D 14757840 (Pubitemid 38167102)
16. J Weaver E Downs-Kelly JR Goldblum, et al. 2008 Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms Mod Pathololgy 21 8 943 949 1:CAS:528:DC%2BD1cXovV2msr8%3D 10.1038/modpathol.2008.84
17. M Schiebe P Ohneseit W Hoffmann R Meyermann HP Rodemann M Bamberg 2000 Analysis of MDM2 and p53 gene alterations in glioblastomas and its correlation with clinical factors J Neurooncol 49 197 203 1:STN:280:DC%2BD3M7nvF2jsQ%3D%3D 10.1023/A:1006410702284 11212898 (Pubitemid 32106781)
18. I Vanden Bempt P Van Loo M Drijkoningen, et al. 2008 Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 30 4869 4874 10.1200/JCO.2007.13.4296 18794552
19. LT Vassilev 2007 MDM2 inhibitors for cancer therapy Trens Mol Med 13 23 31 1:CAS:528:DC%2BD2sXis1CrsQ%3D%3D 10.1016/j.molmed.2006.11.002 (Pubitemid 46027725)
20. LT Vassilev BT Vu B Graves, et al. 2004 In vivo activation of the p53 pathway by the small molecule antagonists of MDM2 Science 303 844 848 1:CAS:528:DC%2BD2cXovVKmtA%3D%3D 10.1126/science.1092472 14704432 (Pubitemid 38174664)
21. S Shangary D Qin D McEachern, et al. 2008 Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc Natl Acad Sci 105 10 3933 3938 1:CAS:528: DC%2BD1cXjs1Ohtb4%3D 10.1073/pnas.0708917105 18316739 (Pubitemid 351723502)
22. S Shangary S Wang 2009 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu Rev Pharmacol Toxicol 49 223 241 1:CAS:528: DC%2BD1MXisV2jsLY%3D 10.1146/annurev.pharmtox.48.113006.094723 18834305
23. MP Dickens R Fitzgerald PM Fischer 2010 Small-molecule inhibitors of MDM2 as new anticancer therapeutics Semin Cancer Biol 20 10 18 1:CAS:528: DC%2BC3cXlsFSisLY%3D 10.1016/j.semcancer.2009.10.003 19897042
24. AS Azmi A Aboukameel S Banerjee, et al. 2010 MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function Eur J Cancer 46 6 1122 1131 1:CAS:528: DC%2BC3cXjs1altLw%3D 10.1016/j.ejca.2010.01.015 20156675
25. AS Azmi PA Philip A Aboukameel, et al. 2010 Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy Curr Cancer Drug Targets 10 3 319 331 1:CAS:528:DC%2BC3cXns1Sntrw%3D 10.2174/156800910791190229 20370686
26. C Tovar J Rosinski Z Filipovic, et al. 2006 Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc Natl Acad Sci USA 103 1888 1893 1:CAS:528:DC%2BD28XhslehtLs%3D 10.1073/pnas.0507493103 16443686 (Pubitemid 43228788)
27. GL Bond C Menin R Bertorelle P Alhopuro LA Aaltonen AJ Levine 2006 MDM2 SNP309 accelerates colorectal tumour formation in women J Med Genet 43 950 952 1:CAS:528:DC%2BD2sXhtVOgtrs%3D 10.1136/jmg.2006.043539 16825430 (Pubitemid 46080193)
28. GL Bond KM Hirshfield T Kirchhoff, et al. 2006 MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 66 5104 5110 1:CAS:528:DC%2BD28XksF2isr0%3D 10.1158/0008-5472.CAN-06-0180 16707433 (Pubitemid 43844932)
29. C Ohtsubo D Shiokawa M Kodama, et al. 2009 Cytoplasmic tethering is involved in synergistic inhibition of p53 by MDMX and MDM2 Cancer Sci 100 7 1291 1299 1:CAS:528:DC%2BD1MXosl2ktbY%3D 10.1111/j.1349-7006.2009.01180.x 19432880
30. R Broll A Stark U Windhovel, et al. 1999 Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas Eur J Cancer 35 7 1083 1088 1:STN:280:DC%2BD3c%2FgtlKntw%3D%3D 10.1016/S0959-8049(99)00058-1 10533452 (Pubitemid 29339191)
31. KY Lam CY Lo NMS Wat JM Luk KSL Lam 2001 The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas J Clin Pathol 54 443 448 1:STN:280:DC%2BD3M3ps1Olsw%3D%3D 10.1136/jcp.54.6.443 11376017 (Pubitemid 32531093)
32. Hori1 M, Shimazaki1 J, Inagawa1 S et al (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71:77-84
33. X-P Hao T Günther A Roessner AB Price IC Talbot 1998 Expression of mdm2 and p53 in epithelial neoplasms of the colorectum J Clin Pathol Mol Pathol 51 26 29 1:STN:280:DyaK1c3oslCquw%3D%3D 10.1136/mp.51.1.26 (Pubitemid 28157353)